Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2018

View Archived Issues

Cipher acquires Correvio's Canadian business portfolio

Sumitomo Dainippon updates pipeline activities of fourth quarter of fiscal 2017

NIAID files IND application for phase IIa study of next-generation pertussis vaccine BPZE-1

Phase III study of galcanezumab in episodic cluster headache meets primary endpoint

FDA grants orphan drug designation to Sarconeos for Duchenne muscular dystrophy

Preliminary results reported from phase Ia/b study of LY-3300054 for solid tumors

SNP in ITGA4 gene tied to higher risk of Alzheimer's disease

Hospira obtains FDA approval for epoetin alfa biosimilar Retacrit

FogPharma announces closing of series B financing

Caladrius Biosciences initiates phase II study of CLBS-14

EC approves Repatha for prevention of heart attack and stroke in established cardiovascular disease

FDA approves Lucemyra to mitigate opioid withdrawal symptoms

FDA accepts Turnstone Biologics' IND for MG1-HPV

Emulate and AstraZeneca enter Organs-on-Chips technology agreement

Flash Therapeutics created from Vectalys and FlashCell merger

FDA awards rare pediatric disease designation to CCP-020

FDA grants rare pediatric disease designation to MYO-101 for limb girdle muscular dystrophy type 2E

FluGen's M2SR influenza vaccine begins challenge study

First phase III clinical results presented for esketamine in treatment-resistant depression

KalVista Pharmaceuticals develops new agents for diabetic retinopathy

Eiger Biopharmaceuticals obtains rights to lonafarnib for Hutchinson-Gilford progeria syndrome

IDMC recommends continuation of enrollment in phase IIa study of milciclib in HCC

European Commission approves Cabometyx for first-line treatment of advanced RCC

Eleven Biotherapeutics changes name to Sesen Bio

Novo Nordisk expands chronic disease focus beyond type 1 diabetes

Bayer patents new vasopressin V1A and V2 receptor antagonists

Boehringer Ingelheim discloses FFAR1 agonists

Bayer and collaborators present DHODH inhibitors

Idenix Pharmaceuticals and Merck identify HIV-1 inhibitors

Researchers divulge SERDs for ER-positive breast cancer

UCB reports topline data from phase III study of Cimzia for nonradiographic axial spondyloarthritis